About this trial
The brown seaweed species Ascophyllum nodosum is rich in bioactive polysaccharides, proteins, peptides, lipids, pigments, and polyphenols. Similarly, Montmorency tart cherry (Prunus cerasus L.) is high in anthocyanins and polyphenols. Both substances have antioxidant, anti-inflammatory, and vasodilatory properties that target mechanisms central to hypertension and cardiometabolic diseases.
Dietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. Previous randomized trial has shown that both brown seaweed and tart cherry supplementation can improving systolic blood pressure and other cardiovascular/ blood lipids. However, to date, no research has explored a seaweed - tart cherry blend using a placebo randomized intervention in patients with hypertension.
The primary purpose of the proposed investigation is to test the ability of a seaweed - tart cherry supplementation blend to improve cardiometabolic parameters in participants with mild-moderate hypertension using a pilot/ feasibility study.
Eligibility criteria
Qualifiers
Aged from 18-65 years
Systolic blood pressure 120 to 139 mmHg
Not taking prescribed medicine for blood pressure management
Ability to complete written questionnaires independently
Disqualifiers
Diagnosed with diabetes mellitus and/ or coronary heart disease
Pregnant and lactating women
Allergy to peppermint
Habitual consumption of peppermint products
Trial design
Treatments tested in this trial
- Brown seaweed and tart cherry blend
- Placebo